6541 Stock Overview
A biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tanvex BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$65.10 |
| 52 Week High | NT$80.00 |
| 52 Week Low | NT$35.05 |
| Beta | 0.45 |
| 1 Month Change | -9.96% |
| 3 Month Change | -5.38% |
| 1 Year Change | 0% |
| 3 Year Change | -64.75% |
| 5 Year Change | -48.90% |
| Change since IPO | -83.17% |
Recent News & Updates
Shareholder Returns
| 6541 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 6.0% | 1.6% | 0.4% |
| 1Y | 0% | 2.1% | 27.0% |
Return vs Industry: 6541 underperformed the TW Biotechs industry which returned 2.1% over the past year.
Return vs Market: 6541 underperformed the TW Market which returned 27% over the past year.
Price Volatility
| 6541 volatility | |
|---|---|
| 6541 Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6541 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6541's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 139 | Stephen Lam | www.tanvex.com |
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial.
Tanvex BioPharma, Inc. Fundamentals Summary
| 6541 fundamental statistics | |
|---|---|
| Market cap | NT$10.42b |
| Earnings (TTM) | -NT$1.62b |
| Revenue (TTM) | NT$40.96m |
260.8x
P/S Ratio-6.6x
P/E RatioIs 6541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6541 income statement (TTM) | |
|---|---|
| Revenue | NT$40.96m |
| Cost of Revenue | NT$30.11m |
| Gross Profit | NT$10.85m |
| Other Expenses | NT$1.63b |
| Earnings | -NT$1.62b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.88 |
| Gross Margin | 26.49% |
| Net Profit Margin | -3,958.87% |
| Debt/Equity Ratio | 0% |
How did 6541 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 11:44 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tanvex BioPharma, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| null null | KGI Securities Co. Ltd. |